Home

baseball Distribuere Habubu sage 217 breakthrough veteran Lignende medier

Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha

Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire

sage-10k_20191231.htm
sage-10k_20191231.htm

Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston

Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace

SEC Filing | Sage Therapeutics, Inc.
SEC Filing | Sage Therapeutics, Inc.

Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd

SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total

Sage advice: psychiatric drug development is tough | Evaluate
Sage advice: psychiatric drug development is tough | Evaluate

Sage advice: psychiatric drug development is tough | Evaluate
Sage advice: psychiatric drug development is tough | Evaluate

Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology

Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha

Bipolar Depression: How do we treat it?
Bipolar Depression: How do we treat it?

Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert

Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha

Small Clinical Trials Lead To Big Results
Small Clinical Trials Lead To Big Results

Rx Product News: April 2023
Rx Product News: April 2023

Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019

sage-10k_20181231.htm
sage-10k_20181231.htm

Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days